 |
|
|
| |
Comparison of Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin
Between Asian and Western HCV GT1b-infected Patients
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Lai Wei1, Yan Luo2, Wang-Long Chuang3, Seung Woon Paik4, Ming-Lung Yu5, Linda M Fredrick2, Andrew Campbell2, Roger Trinh2, Jeffrey Enejosa2, Nancy S Shulman2, Sarah Kopecky-Bromberg2, Jeong Heo6, Niloufar Mobashery2
1Peking University People's Hospital, Beijing, China; 2AbbVie Inc., North Chicago, Illinois, United States; 3Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 4Department of Medicine, Samsung Medical Center, Sungkyunkwan, Republic of Korea; 5Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 6Department of Internal Medicine, College of Medicine, Pusan Nati onal University and Medical Research Insti tute, Pusan Nati onal University Hospital, Busan, Republic of Korea
|
| |
|
|
|
|
|
